Your browser doesn't support javascript.
loading
Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial.
Barginear, Myra F; Gralla, Richard J; Bradley, Thomas P; Ali, Syed S; Shapira, Iuliana; Greben, Craig; Nier-Shoulson, Nanette; Akerman, Meredith; Lesser, Martin; Budman, Daniel R.
Afiliación
  • Barginear MF; Hofstra North Shore-LIJ School of Medicine, Monter Cancer Center, Lake Success, NY, USA. MBarginear@nshs.edu
Support Care Cancer ; 20(11): 2865-72, 2012 Nov.
Article en En | MEDLINE | ID: mdl-22421738
BACKGROUND: The benefit of adding a vena cava filter to anticoagulation in treating cancer patients with venous thromboembolism remains controversial. We initiated this study as the first prospectively randomized trial to evaluate the addition of a vena cava filter placement to anticoagulation with the factor Xa inhibitor fondaparinux sodium in patients with cancer. METHODS: Sixty-four patients with deep vein thrombosis (86 %) and/or pulmonary embolism (55 %) were randomly assigned to receive anticoagulation with fondaparinux sodium with or without a vena cava filter. Endpoints included rates of complications by treatment arm, recurrent thromboembolism, complete resolution of thromboembolism, and survival rates. RESULTS: No patient had a recurrent deep vein thrombosis; two (3 %) patients had new pulmonary emboli, one in each randomized cohort. Major bleeding occurred in three patients (5 %). Two patients on the vena cava filter arm (7 %) had complications from the filter. Median survivals were 493 days in the anticoagulation only arm and 266 days for anticoagulation + vena cava filter (p < 0.57). Complete resolution of venous thromboembolism occurred in 51 % of patients within 8 weeks of initiating anticoagulation. CONCLUSIONS: No advantage was found for placement of a vena cava filter in addition to anticoagulation with fondaparinux sodium in terms of safety, recurrent thrombosis, recurrent pulmonary embolism, or survival in this prospective randomized trial evaluating anticoagulation plus a vena cava filter in cancer patients. Favorable complete resolution rates of thrombosis were observed on both study arms.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Polisacáridos / Filtros de Vena Cava / Tromboembolia Venosa / Anticoagulantes Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Support Care Cancer Asunto de la revista: NEOPLASIAS / SERVICOS DE SAUDE Año: 2012 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Polisacáridos / Filtros de Vena Cava / Tromboembolia Venosa / Anticoagulantes Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Support Care Cancer Asunto de la revista: NEOPLASIAS / SERVICOS DE SAUDE Año: 2012 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania